Study of ADARx Treatment for Kidney Disease in Chinese Adults
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new ADARx medicine in Chinese adults with specific types of kidney disease (IgAN, C3G, or IC-MPGN). The goal is to see if this treatment can slow kidney damage and help preserve kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have kidney disease confirmed by a kidney biopsy (IgAN, C3G, or IC-MPGN)
- Your kidney function (eGFR) is at least 30 mL/min/1.73m² (moderate to mild kidney disease)
- You have not had a kidney transplant or other major organ transplant
- You have not needed dialysis or other kidney replacement therapy for more than 3 days
- You are willing to receive required vaccinations
- You do not have active tuberculosis, HIV, or other serious ongoing infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called ADX-038 for people with certain types of kidney disease that are driven by the complement system (a part of the immune system). The study aims to see if ADX-038 can help slow down or improve kidney function.
This trial tests an experimental medication (ARGX-121) to see if it can reduce protein in your urine, which is a sign of kidney damage in IgA nephropathy. If you qualify, you may receive the study drug and help researchers learn if it's safe and effective.
This trial tests a medication called atrasentan to see if it helps protect kidney function in people with IgA nephropathy, a kidney disease. It may slow down kidney damage and reduce protein in the urine.
This study tests an experimental oral therapy called ADX-097 for people with three types of kidney disease: IgA nephropathy, lupus nephritis, or C3 glomerulopathy. The goal is to see if it’s safe and can help reduce kidney damage.
This trial tests a new cell therapy called GT719 that targets B cells, part of the immune system that attacks the kidneys in several types of autoimmune kidney disease. It is designed for people whose kidney disease has not improved with standard treatments.
This trial tests an investigational medication for two rare kidney conditions that cause inflammation and protein in the urine. It aims to see if the drug is safe and helps control the disease, potentially slowing kidney damage.
Hear when a new Immunoglobulin A Nephropathy (IgAN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.